Latest Uroplasty Inc. Stories

OAB patients treated with Urgent® PC over 36 months sustained their urinary symptom improvement MINNEAPOLIS, May 10, 2013 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ:UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today highlighted the 3-year results of the STEP Study on percutaneous tibial nerve stimulation (PTNS) treatments for overactive bladder (OAB) using Uroplasty's Urgent(®) PC...

~David Kaysen Resigns~ MINNEAPOLIS, April 5, 2013 /PRNewswire/-- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative products to treat voiding dysfunctions, announced today that David B. Kaysen has tendered his resignation as President, Chief Executive Officer and a member of the Board of Directors, effective April 5, 2013. Independent director Robert C. Kill has been named interim Chief Executive Officer while the...

MINNEAPOLIS, March 7, 2013 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, announced today that David Kaysen, President and CEO, and Darin Hammers, Vice President of US Sales, will present the Company's business strategy and financial results at the 25th Annual ROTH Growth Stock Conference at 8:30 AM PT on Monday, March 18, 2013 at The Ritz Carlton in Dana...

MINNEAPOLIS, Feb. 25, 2013 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ:UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced there will be several presentations on the office-based Urgent PC Neuromodulation System at professional society meetings in February and March 2013. Society for Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU), February 27 -March 2,...

MINNEAPOLIS, Feb. 5, 2013 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced changes in its executive leadership for its US sales organization. Effective February 11, 2013, Darin Hammers will assume the role of Vice President of US Sales. In his new role, Mr. Hammers will have responsibility for the US sales force, inside sales support and...

MINNEAPOLIS, Jan. 14, 2013 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI) announced today that it will release financial results for the third quarter of fiscal 2013 ended December 31, 2012 at the market close on Thursday, January 24, 2013. The Company will host a conference call to discuss these results on Thursday, January 24, 2013 at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). David Kaysen, President and Chief Executive Officer, and Medi Jiwani, Vice President, Chief Financial...

MINNEAPOLIS, Dec. 6, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ:UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today highlighted results of a study that compared the cost effectiveness of neuromodulation therapies for Overactive Bladder (OAB) patients over two years of treatment. The study compared percutaneous tibial nerve stimulation (PTNS) delivered via Uroplasty's Urgent(®) PC...

MINNEAPOLIS, Dec. 5, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced its participation in the Oppenheimer 23(rd) Annual Healthcare Conference on Thursday, December 13, 2012, at 1:00 p.m. ET at the Waldorf Hotel in New York. Medi Jiwani, Chief Financial Officer, will present and meet with investors one on one at the conference...

MINNEAPOLIS, Nov. 27, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today announced significant new coverage decisions by private payers and Medicare. Effective October 2012, Health Net(®), one of the largest private insurance payers in California, began covering posterior tibial nerve stimulation (PTNS) for the treatment of overactive bladder...

MINNEAPOLIS, Nov. 6, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that it will participate in two upcoming investor conferences in November - the Stephens Fall Investment Conference and the Lazard 9(th) Annual Healthcare Conference. Detailed information is provided below: What: Stephens Fall...